BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: den Hoed CM, van Blankenstein M, Dees J, Kuipers EJ. The minimal incubation period from the onset of Barrett’s oesophagus to symptomatic adenocarcinoma. Br J Cancer. 2011;105:200-205. [PMID: 21673678 DOI: 10.1038/bjc.2011.214] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Niroomand E, Kumar SR, Goldberg D, Kumar S. Impact of Medicaid Expansion on Incidence and Mortality from Gastric and Esophageal Cancer. Dig Dis Sci 2022. [PMID: 35972583 DOI: 10.1007/s10620-022-07659-6] [Reference Citation Analysis]
2 Sawas T, Majzoub AM, Haddad J, Tielleman T, Nayfeh T, Yadlapati R, Singh S, Kolb J, Vajravelu RK, Katzka DA, Wani S; Post-Endoscopy Esophageal Adenocarcinoma Consensus Panel. Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022;20:e31-50. [PMID: 33901662 DOI: 10.1016/j.cgh.2021.04.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
3 Nucci D, Marino A, Realdon S, Nardi M, Fatigoni C, Gianfredi V. Lifestyle, WCRF/AICR Recommendations, and Esophageal Adenocarcinoma Risk: A Systematic Review of the Literature. Nutrients 2021;13:3525. [PMID: 34684526 DOI: 10.3390/nu13103525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Kroupa R, Katinova I, Pavlik T, Kunovsky L, Prochazka V, Borilova Linhartova P, Packova B, Kala Z, Dolina J. Incidence trends of esophageal cancer in the Czech Republic by histological subtype and stage and prescription rate of acid suppressing drugs. Cancer Epidemiol 2020;69:101853. [PMID: 33161372 DOI: 10.1016/j.canep.2020.101853] [Reference Citation Analysis]
5 Acosta AM, Sholl LM, Fanelli GN, Gordetsky JB, Baniak N, Barletta JA, Lindeman NI, Hirsch MS. Intestinal metaplasia of the urinary tract harbors potentially oncogenic genetic variants. Mod Pathol 2021;34:457-68. [PMID: 32860003 DOI: 10.1038/s41379-020-00655-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Maitra I, Date RS, Martin FL. Towards screening Barrett's oesophagus: current guidelines, imaging modalities and future developments.Clin J Gastroenterol. 2020;13:635-649. [PMID: 32495144 DOI: 10.1007/s12328-020-01135-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kuipers EJ, Spaander MC. Natural History of Barrett's Esophagus. Dig Dis Sci 2018;63:1997-2004. [PMID: 29905908 DOI: 10.1007/s10620-018-5161-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
8 Gatenby P, Bhattacharjee S, Wall C, Caygill C, Watson A. Risk stratification for malignant progression in Barrett’s esophagus: Gender, age, duration and year of surveillance. World J Gastroenterol 2016; 22(48): 10592-10600 [PMID: 28082811 DOI: 10.3748/wjg.v22.i48.10592] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
9 Snider EJ, Freedberg DE, Abrams JA. Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci 2016;61:2217-25. [PMID: 27068172 DOI: 10.1007/s10620-016-4155-9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
10 Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, Katzka DA. Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology 2016;150:599-607.e7; quiz e14-5. [PMID: 26619962 DOI: 10.1053/j.gastro.2015.11.040] [Cited by in Crossref: 109] [Cited by in F6Publishing: 115] [Article Influence: 15.6] [Reference Citation Analysis]
11 Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am 2015;44:203-31. [PMID: 26021191 DOI: 10.1016/j.gtc.2015.02.001] [Cited by in Crossref: 136] [Cited by in F6Publishing: 141] [Article Influence: 17.0] [Reference Citation Analysis]
12 Fujita M, Nakamura Y, Kasashima S, Furukawa M, Misaka R, Nagahara H. Risk factors associated with Barrett’s epithelial dysplasia. World J Gastroenterol 2014; 20(15): 4353-4361 [PMID: 24764673 DOI: 10.3748/wjg.v20.i15.4353] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Massl R, van Blankenstein M, Jeurnink S, Hermans JJ, de Haan MC, Stoker J, Koek M, Niessen WJ, Steyerberg EW, Looman CW, Kuipers EJ. Visceral adipose tissue: the link with esophageal adenocarcinoma. Scand J Gastroenterol 2014;49:449-57. [PMID: 24467299 DOI: 10.3109/00365521.2013.873818] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
14 Armstrong D. Epidemiology of GERD, Barrett's Esophagus and Esophageal Cancer. GI Epidemiology 2014. [DOI: 10.1002/9781118727072.ch13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 de Jonge PJ, van Blankenstein M, Grady WM, Kuipers EJ. Barrett's oesophagus: epidemiology, cancer risk and implications for management. Gut 2014;63:191-202. [PMID: 24092861 DOI: 10.1136/gutjnl-2013-305490] [Cited by in Crossref: 88] [Cited by in F6Publishing: 69] [Article Influence: 9.8] [Reference Citation Analysis]